Harmony Biosciences Holdings, Inc. (HRMY) Insider Trading Activity

NASDAQ$41.52
Market Cap
$2.4B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
583 of 852
Rank in Industry
341 of 491

HRMY Insider Trading Activity

HRMY Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$3,493,972
7
100

Related Transactions

Dayno Jeffrey M.PRESIDENT, CEO
0
$0
1
$237,957
$-237,957
Budur KumarCHIEF MEDICAL OFFICER
0
$0
2
$1.45M
$-1.45M
Kapadia SandipCHIEF FINANCIAL OFFICER
0
$0
4
$1.8M
$-1.8M

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Insider Activity of Harmony Biosciences Holdings, Inc.

Over the last 12 months, insiders at Harmony Biosciences Holdings, Inc. have bought $0 and sold $3.49M worth of Harmony Biosciences Holdings, Inc. stock.

On average, over the past 5 years, insiders at Harmony Biosciences Holdings, Inc. have bought $0 and sold $87.75M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 7,844 shares for transaction amount of $269,049 was made by Nielsen Jack (director) on 2020‑08‑26.

List of Insider Buy and Sell Transactions, Harmony Biosciences Holdings, Inc.

2026-09-08SaleBudur KumarCHIEF MEDICAL OFFICER
28,454
0.0502%
$42.96
$1.22M
-1.31%
2026-09-04SaleBudur KumarCHIEF MEDICAL OFFICER
5,500
0.0094%
$41.98
$230,911
-1.61%
2026-01-26SaleKapadia SandipCHIEF FINANCIAL OFFICER
3,746
0.0065%
$37.15
$139,171
-9.93%
2026-01-15SaleKapadia SandipCHIEF FINANCIAL OFFICER
20,961
0.0359%
$35.92
$752,833
-6.72%
2025-12-12SaleDayno Jeffrey M.PRESIDENT, CEO
5,933
0.0102%
$40.11
$237,957
-13.06%
2025-12-05SaleKapadia SandipCHIEF FINANCIAL OFFICER
20,000
0.0345%
$39.54
$790,896
-11.27%
2025-11-21SaleKapadia SandipCHIEF FINANCIAL OFFICER
3,427
0.0061%
$35.00
$119,945
+3.34%
2025-08-15SaleKapadia SandipCHIEF FINANCIAL OFFICER
21,573
0.0371%
$36.50
$787,378
-9.10%
2025-04-01SaleKapadia SandipCHIEF FINANCIAL OFFICER
6,987
0.0122%
$32.54
$227,386
+4.87%
2025-03-03SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
4,869
0.0086%
$32.67
$159,090
+6.25%
2025-01-27SaleKapadia SandipCHIEF FINANCIAL OFFICER
1,775
0.0031%
$38.05
$67,547
-10.48%
2025-01-27SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
1,629
0.0029%
$38.02
$61,941
-10.48%
2025-01-24SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
13,125
0.0227%
$37.31
$489,634
-9.93%
2025-01-21SaleKapadia SandipCHIEF FINANCIAL OFFICER
25,000
0.0435%
$40.18
$1M
-15.37%
2025-01-21SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
1,123
0.0019%
$40.00
$44,920
-15.37%
2025-01-21SaleDayno Jeffrey M.PRESIDENT, CEO
19,293
0.0335%
$40.13
$774,245
-15.37%
2025-01-16SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
29,475
0.0506%
$37.41
$1.1M
-11.16%
2025-01-15SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
10,507
0.0185%
$37.01
$388,841
-7.28%
2025-01-13SaleDierks JeffreyCHIEF COMMERCIAL OFFICER
7,180
0.0128%
$37.04
$265,946
-6.06%
2024-11-05SaleValor IV Pharma Holdings, LLC10 percent owner
600,000
0.9614%
$30.30
$18.18M
+1.84%
Total: 123
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Kapadia SandipCHIEF FINANCIAL OFFICER
24521
0.0424%
$1.02M08
Budur KumarCHIEF MEDICAL OFFICER
13115
0.0227%
$544,534.8002
Dayno Jeffrey M.PRESIDENT, CEO
0
0%
$0011
Valor IV Pharma Holdings, LLC10 percent owner
6618033
11.4316%
$274.78M02
Marshman Fund Trust II10 percent owner
6051120
10.4523%
$251.24M12
<0.0001%
Novo Holdings A/S10 percent owner
4409803
7.6172%
$183.1M10
<0.0001%
Nielsen Jackdirector
2571024
4.441%
$106.75M530
<0.0001%
Wicki Andreasdirector
2147943
3.7102%
$89.18M023
Jacobs John CPRESIDENT, CEO
0
0%
$0010
Dierks JeffreyCHIEF COMMERCIAL OFFICER
0
0%
$0027
Serafin AndrewCHIEF STRATEGY OFFICER
0
0%
$001
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$607,326,766
95
3.56%
$2.44B
$52,263,649
70
1.18%
$2.14B
$54,660,406
66
22.24%
$2.3B
$47,419,530
58
17.20%
$2.16B
$678,065,999
37
-13.32%
$2.26B
$154,047,855
36
79.21%
$2.52B
$27,136,525
32
36.73%
$2.11B
$1,603,489
30
98.90%
$2.46B
$9,463,680
28
0.72%
$2.36B
$69,132,919
24
-22.11%
$2.72B
$73,814,940
15
-4.77%
$2.41B
$114,805,503
13
33.64%
$2.49B
$850,567
12
30.43%
$2.67B
Harmony Biosciences Holdings, Inc.
(HRMY)
$25,073,947
7
-5.99%
$2.4B
$955,480
6
-18.91%
$2.73B
$24,000,085
4
33.26%
$2.69B
$84,600
3
21.39%
$2.15B
$162,238
3
144.37%
$2.09B
$152,517
2
177.13%
$2.15B

HRMY Institutional Investors: Active Positions

Increased Positions179+57.19%8M+16.03%
Decreased Positions139-44.41%5M-9.98%
New Positions55New2MNew
Sold Out Positions30Sold Out367,652Sold Out
Total Postitions353+12.78%50M+6.05%

HRMY Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$258,892.0011.94%6.93M+189,003+2.81%2025-09-30
Vanguard Group Inc$190,532.008.79%5.1M-13,604-0.27%2025-09-30
Fmr Llc$143,800.006.63%3.85M-841,220-17.94%2025-09-30
Dimensional Fund Advisors Lp$63,231.002.92%1.69M+109,405+6.92%2025-09-30
American Century Companies Inc$62,408.002.88%1.67M+168,145+11.2%2025-09-30
State Street Corp$61,812.002.85%1.65M+24,358+1.5%2025-09-30
Lsv Asset Management$59,617.002.75%1.59M+106,391+7.15%2025-09-30
Arrowstreet Capital, Limited Partnership$48,421.002.23%1.3M+388,472+42.84%2025-09-30
Valor Management Llc$47,405.002.19%1.27M-5M-80.84%2025-09-30
Geode Capital Management, Llc$47,034.002.17%1.26M+203,915+19.34%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.